Search research articles
Contact Us
Filters
Showing results (51-60 of 61) with videos related to
Page
of 7
Sort By:
Journal of Medicinal Chemistry
|
August 9, 2018
Identification of an Orally Bioavailable Chromene-Based Selective Estrogen Receptor Degrader (SERD) That Demonstrates Robust Activity in a Model of Tamoxifen-Resistant Breast Cancer
Johnny Nagasawa, Steven Govek, Mehmet Kahraman, et al.
Veterinary Immunology and Immunopathology
|
March 3, 2009
Characterization of alpha(4)beta(1) (CD49d/CD29) on equine leukocytes: potential utility of a potent alpha(4)beta(1) (CD49d/CD29) receptor antagonist in the treatment of equine heaves (recurrent airway obstruction)
Kelly M Treonze, Kenneth Alves, Paul Fischer, et al.
Journal of Medicinal Chemistry
|
April 21, 2009
Discovery of inducible nitric oxide synthase (iNOS) inhibitor development candidate KD7332, part 1: Identification of a novel, potent, and selective series of quinolinone iNOS dimerization inhibitors that are orally active in rodent pain models
Céline Bonnefous, Joseph E Payne, Jeffrey Roppe, et al.
ACS Medicinal Chemistry Letters
|
January 19, 2019
Maximizing ER-α Degradation Maximizes Activity in a Tamoxifen-Resistant Breast Cancer Model: Identification of GDC-0927
Mehmet Kahraman, Steven P Govek, Johnny Y Nagasawa, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
November 2, 2010
Pharmacological characterization of KLYP961, a dual inhibitor of inducible and neuronal nitric-oxide synthases
Kent T Symons, Phan M Nguyen, Mark E Massari, et al.
Bioorganic & Medicinal Chemistry Letters
|
October 15, 2015
Optimization of an indazole series of selective estrogen receptor degraders: Tumor regression in a tamoxifen-resistant breast cancer xenograft
Steven P Govek, Johnny Y Nagasawa, Karensa L Douglas, et al.
Journal of Medicinal Chemistry
|
April 17, 2015
Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts
Andiliy Lai, Mehmet Kahraman, Steven Govek, et al.
Bioorganic & Medicinal Chemistry Letters
|
December 28, 2018
Selective estrogen receptor degraders with novel structural motifs induce regression in a tamoxifen-resistant breast cancer xenograft
Steven P Govek, Celine Bonnefous, Jackaline D Julien, et al.
Molecular Cancer Therapeutics
|
May 17, 2008
KD5170, a novel mercaptoketone-based histone deacetylase inhibitor that exhibits broad spectrum antitumor activity in vitro and in vivo
Christian A Hassig, Kent T Symons, Xin Guo, et al.
Cancer Research
|
January 24, 2012
ARN-509: a novel antiandrogen for prostate cancer treatment
Nicola J Clegg, John Wongvipat, James D Joseph, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 61) with videos related to
Sort By:
Page
of 7
Journal of Medicinal Chemistry
|
August 9, 2018
Identification of an Orally Bioavailable Chromene-Based Selective Estrogen Receptor Degrader (SERD) That Demonstrates Robust Activity in a Model of Tamoxifen-Resistant Breast Cancer
Johnny Nagasawa, Steven Govek, Mehmet Kahraman, et al.
Veterinary Immunology and Immunopathology
|
March 3, 2009
Characterization of alpha(4)beta(1) (CD49d/CD29) on equine leukocytes: potential utility of a potent alpha(4)beta(1) (CD49d/CD29) receptor antagonist in the treatment of equine heaves (recurrent airway obstruction)
Kelly M Treonze, Kenneth Alves, Paul Fischer, et al.
Journal of Medicinal Chemistry
|
April 21, 2009
Discovery of inducible nitric oxide synthase (iNOS) inhibitor development candidate KD7332, part 1: Identification of a novel, potent, and selective series of quinolinone iNOS dimerization inhibitors that are orally active in rodent pain models
Céline Bonnefous, Joseph E Payne, Jeffrey Roppe, et al.
ACS Medicinal Chemistry Letters
|
January 19, 2019
Maximizing ER-α Degradation Maximizes Activity in a Tamoxifen-Resistant Breast Cancer Model: Identification of GDC-0927
Mehmet Kahraman, Steven P Govek, Johnny Y Nagasawa, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
November 2, 2010
Pharmacological characterization of KLYP961, a dual inhibitor of inducible and neuronal nitric-oxide synthases
Kent T Symons, Phan M Nguyen, Mark E Massari, et al.
Bioorganic & Medicinal Chemistry Letters
|
October 15, 2015
Optimization of an indazole series of selective estrogen receptor degraders: Tumor regression in a tamoxifen-resistant breast cancer xenograft
Steven P Govek, Johnny Y Nagasawa, Karensa L Douglas, et al.
Journal of Medicinal Chemistry
|
April 17, 2015
Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts
Andiliy Lai, Mehmet Kahraman, Steven Govek, et al.
Bioorganic & Medicinal Chemistry Letters
|
December 28, 2018
Selective estrogen receptor degraders with novel structural motifs induce regression in a tamoxifen-resistant breast cancer xenograft
Steven P Govek, Celine Bonnefous, Jackaline D Julien, et al.
Molecular Cancer Therapeutics
|
May 17, 2008
KD5170, a novel mercaptoketone-based histone deacetylase inhibitor that exhibits broad spectrum antitumor activity in vitro and in vivo
Christian A Hassig, Kent T Symons, Xin Guo, et al.
Cancer Research
|
January 24, 2012
ARN-509: a novel antiandrogen for prostate cancer treatment
Nicola J Clegg, John Wongvipat, James D Joseph, et al.
Page
of 7